Call to Action
Support the 2025 Freedom to Heal Act
In December 2025, Senators Cory Booker (D-NJ) and Rand Paul (R-KY), and Representatives Madeleine Dean (D-PA) and Nancy Mace (R-SC), introduced the Freedom to Heal Act of 2025 (FTHA) to resolve a statutory conflict between the Right to Try Act and Schedule I of the Controlled Substances Act.
The FTHA establishes a DEA-regulated physician registration process that would allow approved physicians to administer Schedule I “eligible investigational drugs” (EIDs) to treat “eligible patients” in accordance with federal and state Right to Try laws. The bill limits administration to appropriate clinical settings, requires adherence to safety guidance, and grants DEA oversight and rulemaking authority.
Absent this fix, patients with life-threatening conditions who have exhausted approved treatments and cannot participate in clinical trials will continue to have no practical pathway to access care with potentially lifesaving Schedule I EIDs—such as MDMA and psilocybin—despite otherwise qualifying under existing Right to Try law. The FTHA corrects this injustice. Find out more here.
Read the Drug Enforcement Administration's response to Dr. Sue Sisley, Scottsdale Research Institute, providing its interpretation of the conflict between the current RTT law and the Controlled Substances Act.
Learn more about the history of congressional actions taken to address this statutory conflict.
Show Your Support
Please complete the form to sign on in support of the 2025 Freedom to Heal Act (FTHA)